Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-19
2006-09-19
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S023000, C514S054000
Reexamination Certificate
active
07109175
ABSTRACT:
The present invention relates to Ca2+channel blockers and more particularly to the R-type Ca2+channel blockers. More specifically, the invention relates to Ca2+channel blockers activity ofMandevilla velutinaandMandevilla illustris. The present invention further concerns saponin-like compounds isolated fromMandevillaspecies. The present invention also relates to the treatment of several pathologies that involve the nifedipine-insensitive but isradipine sensitive steady-state R-type Ca2+channel and the use of steady-state R-type Ca2+channel blockers in the treatment of these pathologies.
REFERENCES:
patent: 0 359 311 (1990-03-01), None
Edson et al. “The structure of velutinol A is (15R,16R, 20S)-14,16:15,20:16:2triepoxy-15,16-seco-14β,17α-pregn-5-ene-3β,15diol. A combined quantiative Overhauser effect and molecular modeling study” J. Chem. Soc., Perkin Trans. 2, 1996: pp. 1359-1366.
Bkaily et al. “The use of confocal microscopy in the investigation of cell structure and function in the heart, vascular endothelium and smooth muscle cells” Molecular and Cellular Biochemistry 172 (1997): pp. 171-194.
Bkaily et al. “Nuclear Membrane Receptors and Channels: Potential Therapeutical Targets for Drug Action” Drug Development Research 42 (1997): pp. 211-218.
Bkaily et al. “Bradykinin activates R-, T-, and L-type Ca2+channels and induces a sustained increase of nuclear Ca2+in aortic vascular smooth muscle cells1” Can. J. Physiol. Pharmacol. 75 (1997): pp. 652-660.
Bkaily et al. “Increases of T-type Ca2+current in heart cells of the cardiomyopathic hamster” Molecular and Cellular Biochemistry 176 (1997): pp. 199-204.
Bkaily et al. “Modulation of cytosolic and nuclear Ca2+and Na+transport by taurine in heart cells” Molecular and Cellular Biochemistry 170 (1997): pp. 1-8.
Bkaily et al. “Endothelin-1 and insulin activate the steady-state voltage dependent R-type Ca2+channel in aortic smooth muscle cells via a pertussis toxin and cholera toxin sensitive G-protein” Molecular and Cellular Biochemistry 183 (1998): pp. 39-47.
Ghassan Bkaily “Ionic Channels in Vascular Smooth Muscle” R. G. Landes Company (1994).
Vaz et al. “Antinociceptive action of 2-(4-Bromobenzoyl)-3-Methyl-4,6-Dimethoxy Benzofuran, a Novel Xanthoxyline Derivative on Chemical and Thermal Models of Nociception in Mice” The Journal of Pharmacology and Experimental Therapeutics (1996): pp. 304-312.
Neves et al. “Differential effects ofMandevilla velutinacompounds on paw oedema induced by phospholipase A2and phospholipase C” European Journal of Pharmacology 243 (1993): pp. 213-219.
Raman et al. “Effects of Estradiol and Progesterone on Platelet Calcium Responses” American Journal of Hypertension 8 (1995): pp. 197-200.
Frode Saleh et al. “Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy” British Journal of Pharmacology 118 (1996): pp. 811-819.
Zhang et al. “Distinctive Pharmacology and Kinetics of cloned neuronal Ca2channels and their possible counterparts in mammalian CNS neurons” Neuropharmacology vol. 32, No. 11 (1993): pp. 1075-1088.
Randall et al. “Contrasting Biophysical and Pharmacological Properties of T-type and R-type Calcium Channels” Neuropharmacology, vol. 36, No. 7, (1997): pp. 879-893.
Burch et al. “A bradykinin antagonist inhibits carrageenan edema in rats” Archives of Pharmacology 342 (1990): pp. 18993.
Calixto et al. “The selective antagonism of bradykinin action on rat isolated uterus by crudeMandevilla velutinaextract” Br. J. Pharmac 85 (1985): pp. 729-731.
Calixto et al. “Effect of a crude extract ofMandevilla velutinaon contractions induced by bradykinin and [des-Arg9]-bradikinin in isolated vessels of the rabbit” Br. J. Pharmac 88 (1986): pp. 937-941.
Calixto et al. “The competitive antagonistic effect of compounds fromMandevilla velutinaon kinin-induced contractions of rat uterus and guinea-pig ileum in vitro” Br. J. Pharmacol. 94 (1988): pp. 1133-1142.
Compos et al. “Upregulation of B1receptor mediating des-Arg9-BK-induced rat paw oedema by systemic treatment with bacterial endotoxin” British Journal of Pharmacology 117 (1996): pp. 793-798.
Compos et al. “Involvement of B1and B2receptors in bradykinin-induced rat paw oedema” British Journal of Pharmacology 114 (1995): pp. 1005-1013.
Calixto et al. “Antagonism of Kinin-induced contraction of isolated rat uterus by the crude hydroalcoholic extract fromMandevilla illustris” Gen. Pharmac. vol. 22, No. 1 (1991), pp. 99-101.
Calixto et al. “Kinin antagonist activity of compounds fromMandevilla velutinain the rat isolated uterus” Br. J. Pharmac. 91 (1987), pp. 199-204.
Gratton et al. “Pharmacological Properties of Endothelins and Big Endothelins in Ketamine/Xylazine or Urethane Anesthetized Rats” American Journal of Hypertension 8 (1995): pp. 1121-1127.
Damas et al. “Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat” European Journal of Pharmacology 211 (1992): pp. 81-86.
Compos et al. “Antioedematogenic and antinociceptive actions of NPC 18521, a novel bradykinin B2receptor antagonist” European Journal of Pharmacology 316 (1996): pp. 227-286.
Moraes et al. “Jatrophone and 12-o-tetradecanoyl phorbol-13-acetate antagonism of stimulation of natural killer activity and lymphocyte proliferation” European Journal of Pharmacology 312 (1996): pp. 333-339.
Claing et al. “Role of R-type calcium channels in the response of the perfused arterial and venous mesenteric vasculature of the rat to platelet-activating factor” Br. J. Pharmacol. 112 (1994): pp. 1202-1208.
A.J. de Brum-Fernandes et al. “Characterization of the PGE2receptor subtype in bovine chondrocytes in culture” PGE2receptor in bovine chondrocytes: pp. 1597-1604.
Gratton et al. “Different pressor and broncoconstrictor properties of human big-endothelin-1, 2(1-38) and 3 in ketamine/xylazine-anaesthetized guinea-pigs” British Journal of Pharmacology 114 (1995): pp. 720-726.
Levy et al. “Diabetes Mellitus: A Disease of Abnormal Cellular Calcium Metabolism?” The American Journal of Medicine vol. 96 (1994): pp. 260-273.
Hargreaves et al. “Bradykinin is increased during acute and chronic inflammation: Therapeutic implications” Clin Pharmacol Ther (1988): pp. 613-621.
Jacobs et al. “Effect of Weight Reduction on Cellular Cation Metabolism and Vascular Resistance” Hypertension vol. 21, No. 3 (1993): pp. 308-314.
Johnson et al. “A Multicenter Comparison of adverse Reaction Profiles of Isradipine and Enalapril at Equipotent Doses in Patients with Essential Hypertension” J. Clim Pharmacol 35 (1995): pp. 484-492.
Lopez et al. “Spontaneous Calcium Waves Without Contraction in Cardiac Myocytes” Biochemical and Biophysical Research communications vol. 214, No. 3 (1995): pp. 781-787.
Grossman et al. “Cardiovascular Effects of Isradipine in Essential Hypertension” The American Journal of Cardiology vol. 68 (1991): pp. 65-70.
Bkaily Ghassan
Calixto Joao B.
D'Orleans-Juste Pedro
Yunes Rosendo A.
Merchant & Gould P.C.
Peselev Elli
Universite de Sherbrooke
LandOfFree
Specific steady-state R-type CA 2+ channel blockers and use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Specific steady-state R-type CA 2+ channel blockers and use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific steady-state R-type CA 2+ channel blockers and use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3564121